Epinephrine inhalation - G2B Pharma/Shin Nippon Biomedical Laboratories

Drug Profile

Epinephrine inhalation - G2B Pharma/Shin Nippon Biomedical Laboratories

Alternative Names: G2B-011

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator G2B Pharma; Shin Nippon Biomedical Laboratories
  • Class Antiarrhythmics; Antihaemorrhagics; Antihypotensives; Bronchodilators; Catecholamines; Ethanolamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Anaphylaxis

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Anaphylaxis in Japan (Inhalation, Powder)
  • 13 Aug 2014 Sosei receives first right to negotiate for global licensing of epinephrine inhalation
  • 26 Sep 2013 Research programme: Epinephrine inhalation - G2B Pharma/Shin Nippon is available for licensing as of 26 Sep 2013. http://www.snbl-nds.co.jp/en/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top